Vaxart, Inc.
For the period ended May 7, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
May 7, 2026 · Filed May 7, 2026
Use the contents to explore the available documents and sections.
VXRT$0.550.0%Stored close · as of Jul 8, 2026
Contents
EX-99.1 · COVID-19 Program Update
COVID-19 Program Update
| ● | Vaxart’s Phase 2b COVID-19 trial, conducted in collaboration with BARDA, compares the Company’s oral pill vaccine against a commercially available mRNA vaccine. The trial is fully enrolled with approximately 5,400 participants across the two cohorts – Vaxart’s oral pill vs. mRNA injectable. |
| o | The Company is working toward the release of the 12-month safety and immunogenicity data from the 400-person sentinel cohort, which is now anticipated in the second quarter of 2026. |
| ■ | The 400-participant sentinel cohort was designed to assess safety prior to initiating the larger efficacy and safety trial and was not powered to provide a statistically significant comparison between the oral pill and mRNA vaccine groups. |
| ■ | In January 2025, Vaxart announced that an independent Data and Safety Monitoring Board (DSMB), which conducted a planned review of the 30-day safety data from the sentinel cohort of 400 participants, recommended that the study continue without any modifications. |
| o | The primary data readout from the main KP.2 cohort of approximately 5,000 participants is currently anticipated in early 2027. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.